Wang JV, Christman MP, Feng H, et al. - In this randomized, blinded, split‐face, comparative trial, researchers sought to evaluate the utility of a tripeptide/hexapeptide serum as a peri‐procedural adjunct to non‐ablative fractional laser resurfacing. In total, 20 individuals were recruited. Each hemiface was randomized to either tripeptide/hexapeptide serum or bland moisturizer for twice daily application beginning 14 days prior to first laser treatment and lasting until 60 days after. All individuals received 2 treatments to entire face nearly 1 month apart with 1927nm thulium non‐ablative fractional laser. The addition of tripeptide/hexapeptide serum as a peri‐procedural adjunct to non‐ablative fractional laser resurfacing enhanced various clinical measures of photodamage and cutaneous aging and the rapid post‐procedural recovery. The tripeptide/hexapeptide serum has been shown to be safe, well‐tolerated, and well‐liked by participants.